Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MT-4129 in Healthy Subjects
NCT02953132Phase 1Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Nov 2016
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lorundrostat in hypertension (HTN) (2 arms), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoints: Safety and Tolerability as measured by incidence and severity of adverse events, Safety and Tolerability as measured by vital signs and 3 more. Started Nov 2016; status: completed.
02
Drugs
lorundrostat
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT02953132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02953132.